Research
Helicobacter pylori eradication: A randomised comparative trial of 7-day versus 14-day triple therapy
Abstract
Objectives. We compared 7-day and 14-day regimens to determine the optimum duration of triple therapy for H. pylori eradication.
Methods. We undertook a prospective randomised comparative trial of 7-day and 14-day triple therapy regimen for H. pylori eradication at the Aga Khan University Hospital, Nairobi; 120 patients with dyspepsia and H. pylori infection were randomised to receive esomeprazole, amoxicillin and clarithromycin for either 7 days (EAC 7) or 14 days (EAC 14). Compliance and side-effects were assessed 2 weeks after the start of therapy and H. pylori eradication was assessed by stool antigen tests 4 weeks after treatment.
Results. Both the intention-to-treat (ITT; N=120) and per protocol (PP; N=97) analyses showed no significant differences between the eradication rates of EAC 7 (ITT 76.7%; PP 92%) and EAC 14 (ITT 73.3%; PP 93.6%) (ITT p=0.67; PP p=0.76). Poor compliance was reported in one patient in the EAC 14 group. The incidence of adverse events was comparable in the two groups.
Conclusion. One-week and 2-week triple treatments for H. pylori eradication are similar in terms of efficacy, safety and patient compliance.
Authors' affiliations
Ahmed Sokwala, Department of Medicine, Aga Khan University Hospital, Nairobi
Mahesh V Shah, Department of Medicine, Aga Khan University Hospital, Nairobi
Smita Devani, Department of Medicine, Aga Khan University Hospital, Nairobi
Gerald Yonga, Department of Medicine, Aga Khan University Hospital, Nairobi
Cite this article
Article History
Date published: 2012-05-08
Article Views
Full text views: 9580
Comments on this article
*Read our policy for posting comments here